DE4333190C2 - Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung - Google Patents

Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung

Info

Publication number: DE4333190C2
Authority: DE; Germany
Prior art keywords: tablet according; biting; microparticles; active ingredient; tablet
Prior art date: 1993-09-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE19934333190

Other languages

German (de)

English (en)

Other versions

DE4333190A1 (de

Inventor

Werner Korsatko

Brigitte Korsatko

Wolfram Tritthart

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KORSATKO WERNER UNIV PROF DR E

Original Assignee

KORSATKO WERNER UNIV PROF DR E

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-09-29

Filing date

1993-09-29

Publication date

1996-05-30

1993-09-29 Application filed by KORSATKO WERNER UNIV PROF DR E filed Critical KORSATKO WERNER UNIV PROF DR E

1993-09-29 Priority to DE19934333190 priority Critical patent/DE4333190C2/de

1994-09-22 Priority to PCT/EP1994/003166 priority patent/WO1995008988A1/fr

1994-09-22 Priority to EP94928795A priority patent/EP0715515A1/fr

1994-09-22 Priority to AU78088/94A priority patent/AU7808894A/en

1995-03-30 Publication of DE4333190A1 publication Critical patent/DE4333190A1/de

1996-05-30 Application granted granted Critical

1996-05-30 Publication of DE4333190C2 publication Critical patent/DE4333190C2/de

2013-09-30 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000004480 active ingredient Substances 0.000 title claims description 31
230000003111 delayed effect Effects 0.000 title description 6
239000011859 microparticle Substances 0.000 claims description 24
230000001055 chewing effect Effects 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 7
239000011159 matrix material Substances 0.000 claims description 6
239000001913 cellulose Substances 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 5
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 5
229960001259 diclofenac Drugs 0.000 claims description 5
230000000979 retarding effect Effects 0.000 claims description 5
KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical class C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 claims description 4
208000001132 Osteoporosis Diseases 0.000 claims description 3
159000000007 calcium salts Chemical class 0.000 claims description 3
229960001380 cimetidine Drugs 0.000 claims description 3
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 3
238000012423 maintenance Methods 0.000 claims description 3
229960001132 naftidrofuryl Drugs 0.000 claims description 3
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 3
BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 claims description 3
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 2
229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims description 2
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
239000002160 alpha blocker Substances 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000003356 anti-rheumatic effect Effects 0.000 claims description 2
229960002274 atenolol Drugs 0.000 claims description 2
239000002876 beta blocker Substances 0.000 claims description 2
229940097320 beta blocking agent Drugs 0.000 claims description 2
239000011575 calcium Substances 0.000 claims description 2
229910052791 calcium Inorganic materials 0.000 claims description 2
229960002896 clonidine Drugs 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
230000001882 diuretic effect Effects 0.000 claims description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
229960003883 furosemide Drugs 0.000 claims description 2
239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 2
229960002003 hydrochlorothiazide Drugs 0.000 claims description 2
229960003088 loratadine Drugs 0.000 claims description 2
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
NENBAISIHCWPKP-UHFFFAOYSA-N Clofenamide Chemical compound NS(=O)(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NENBAISIHCWPKP-UHFFFAOYSA-N 0.000 claims 1
239000001856 Ethyl cellulose Substances 0.000 claims 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
230000003266 anti-allergic effect Effects 0.000 claims 1
230000003276 anti-hypertensive effect Effects 0.000 claims 1
239000003435 antirheumatic agent Substances 0.000 claims 1
230000000740 bleeding effect Effects 0.000 claims 1
229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
239000000470 constituent Substances 0.000 claims 1
150000002148 esters Chemical class 0.000 claims 1
229920001249 ethyl cellulose Polymers 0.000 claims 1
235000019325 ethyl cellulose Nutrition 0.000 claims 1
229960004667 ethyl cellulose Drugs 0.000 claims 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
230000001737 promoting effect Effects 0.000 claims 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 1
229960000620 ranitidine Drugs 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
230000024883 vasodilation Effects 0.000 claims 1
239000003826 tablet Substances 0.000 description 21
239000007910 chewable tablet Substances 0.000 description 8
239000002775 capsule Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
229920003134 Eudragit® polymer Polymers 0.000 description 3
159000000003 magnesium salts Chemical class 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000009747 swallowing Effects 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229940068682 chewable tablet Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000011775 sodium fluoride Substances 0.000 description 2
235000013024 sodium fluoride Nutrition 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229960005336 magnesium citrate Drugs 0.000 description 1
239000004337 magnesium citrate Substances 0.000 description 1
235000002538 magnesium citrate Nutrition 0.000 description 1
239000000395 magnesium oxide Substances 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
229940074371 monofluorophosphate Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
239000011734 sodium Substances 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DE19934333190 1993-09-29 1993-09-29 Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung Expired - Fee Related DE4333190C2 (de)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
DE19934333190 DE4333190C2 (de)	1993-09-29	1993-09-29	Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung
PCT/EP1994/003166 WO1995008988A1 (fr)	1993-09-29	1994-09-22	Comprime contenant une masse de base contenant le cas echeant des principes actifs et des microparticules contenant des principes actifs
EP94928795A EP0715515A1 (fr)	1993-09-29	1994-09-22	Comprime contenant une masse de base contenant le cas echeant des principes actifs et des microparticules contenant des principes actifs
AU78088/94A AU7808894A (en)	1993-09-29	1994-09-22	Tablet containing a basic material possibly containing active substances and active substance containing microparticles

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19934333190 DE4333190C2 (de)	1993-09-29	1993-09-29	Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung

Publications (2)

Publication Number	Publication Date
DE4333190A1 DE4333190A1 (de)	1995-03-30
DE4333190C2 true DE4333190C2 (de)	1996-05-30

Family

ID=6498970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE19934333190 Expired - Fee Related DE4333190C2 (de)	1993-09-29	1993-09-29	Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung

Country Status (4)

Country	Link
EP (1)	EP0715515A1 (fr)
AU (1)	AU7808894A (fr)
DE (1)	DE4333190C2 (fr)
WO (1)	WO1995008988A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69724424T2 (de) *	1996-05-13	2004-06-24	Novartis Consumer Health S.A.	Mundfreisetzungssystem
DE19648576C2 (de) *	1996-11-23	1999-08-12	Lohmann Therapie Syst Lts	Lutschtablette zur modifizierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt
AR017512A1 (es)	1997-08-22	2001-09-12	Smithkline Beecham Corp	Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es)	1997-08-22	2001-08-01	Smithkline Beecham Corp	PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
FR2865648B1 (fr) *	2004-02-03	2006-06-30	Philippe Perovitch	Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2453639A1 (fr) *	1979-04-09	1980-11-07	Sanofi Sa	Composition medicamenteuse a liberation programmee immediate-retard a base de naftidrofuryl
EP0207405B1 (fr) *	1982-07-27	1990-03-21	Mylan Pharmaceuticals, Inc.	Procédé pour la préparation d'une composition pharmaceutique combinée sous la forme d'une dose unitaire hétérogène de granulés possédant une biodisponibilité accrue
DK62184D0 (da) *	1984-02-10	1984-02-10	Benzon As Alfred	Diffusionsovertrukket polydepotpraeparat
SE450087B (sv) *	1985-10-11	1987-06-09	Haessle Ab	Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4861590A (en) *	1986-09-25	1989-08-29	Colgate-Palmolive Company	Sustained release fluoride and calcium composition
ATE73328T1 (de) *	1987-05-08	1992-03-15	Smith Kline French Lab	Pharmazeutische zusammensetzungen.
JP2514078B2 (ja) *	1988-08-22	1996-07-10	エスエス製薬株式会社	圧縮成型製剤
US4927639A (en) *	1989-02-02	1990-05-22	Warner-Lambert Company	Modified release gemfibrozil composition
BE1004243A3 (fr) *	1990-05-17	1992-10-20	Europharmaceuticals Sa	Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation.
DE4108239A1 (de) *	1991-03-14	1992-09-17	Merck Patent Gmbh	Pellets enthaltend natriummonofluorphosphat
ES2079743T3 (es) *	1991-07-01	1996-01-16	Gergely Gerhard	Tableta para chupar o masticar.
FR2679451B1 (fr) *	1991-07-22	1994-09-09	Prographarm Laboratoires	Comprime multiparticulaire a delitement rapide.
DE4236090C1 (de) *	1992-10-26	1994-01-05	Asta Medica Arzneimittel	Pharmazeutische Zubereitung für die Fluoridionen-Versorgung

1993
- 1993-09-29 DE DE19934333190 patent/DE4333190C2/de not_active Expired - Fee Related
1994
- 1994-09-22 WO PCT/EP1994/003166 patent/WO1995008988A1/fr not_active Ceased
- 1994-09-22 EP EP94928795A patent/EP0715515A1/fr not_active Withdrawn
- 1994-09-22 AU AU78088/94A patent/AU7808894A/en not_active Abandoned

Also Published As

Publication number	Publication date
AU7808894A (en)	1995-04-18
DE4333190A1 (de)	1995-03-30
EP0715515A1 (fr)	1996-06-12
WO1995008988A1 (fr)	1995-04-06

Publication	Publication Date	Title
DE69230475T2 (de)	2000-07-13	Verzögerte Freigabe Matrix für Arzneimittel
DE69225135T2 (de)	1998-08-20	Dosierungsform zur verzoegerten wirkstofffreisetzung
DE69629797T2 (de)	2004-07-15	Matrix zur gesteuerten freisetzung von arzneistoffen
DE3689983T2 (de)	1995-02-23	Arzneimittel mit langsamer Wirkstofffreisetzung.
DE3811114C2 (de)	1996-05-30	Zweischichtige Dosierungsform zur Abgabe eines Wirkstoffs
DE69316715T2 (de)	1998-07-16	Mehrschichtige Matrixsysteme mit kontrollierter Wirkstoffabgabe
DE60034565T2 (de)	2007-12-27	Verfahren zur herstellung eines umhüllten geschmackmaskierten granulats mit sofortiger wirkstofffreisetzung
DE69109286T2 (de)	1995-09-28	Pharmazeutische zusammensetzung.
DE60117801T2 (de)	2006-11-23	Pharmazeutische zusammensetzung mit gesteuerter freigabe und verzögerter absorption
DE69518820T2 (de)	2001-02-22	Rotogranulat und Beschichtung von Acetaminophen, Pseudoephedrin, Chlorpheniramin und, gegebenenfalls, Dextromethorphan
DE3715224A1 (de)	1987-11-12	Dosierungsform zur stossweisen freisetzung eines arzneimittels
DD286107A5 (de)	1991-01-17	Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt
DE3727615C2 (de)	1997-05-22	Pharmazeutische Zubereitung für die Fluorid- und Calciumionen-Versorgung
WO1998056355A1 (fr)	1998-12-17	Preparations pharmaceutiques a liberation controlee contenant un inhibiteur de l'enzyme de conversion de l'angiotensine comme principe actif
EP0208144B1 (fr)	1989-09-20	Granulé pharmaceutique contenant de l'ambroxol ou de la bromhexine
AT405134B (de)	1999-05-25	Furanderivate enthaltende pharmazeutische präparate
DE4333190C2 (de)	1996-05-30	Zerbeißtablette mit verzögerter Wirkstoff-Freisetzung
DE69307807T2 (de)	1997-05-15	Naproxen-Tabletten mit gesteuerter Wirkstoffabgabe
DE69104396T2 (de)	1995-02-09	Pharmazeutische Zubereitung.
DE69813083T2 (de)	2004-05-27	Kombination in feste Dosiermenge von Angiotensin-Converting-Enzyme-Hemmern mit Calcium-Kanal Antagonisten zur Behandlung von Herz-Kreislauferkrankungen
EP1121109B1 (fr)	2006-05-31	Formulation a liberation biphasique contenant du tramadol
EP0641200B1 (fr)	1998-12-02	Compositions d'acide 2-arylpropionique et leur procede de preparation
DE10152351B4 (de)	2005-09-22	Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
EP1847258B1 (fr)	2010-04-21	Compositions pharmaceutiques comprenant thieno[3,2-c]pyridine comme agent active et des glycérols partielles comme lubrifiante
DE69224793T2 (de)	1998-11-19	Magnesiumhaltiges Arzneimittel mit verlängerter Wirkstoffabgabe

Legal Events

Date	Code	Title
1995-03-30	OP8	Request for examination as to paragraph 44 patent law
1996-05-30	D2	Grant after examination
1996-11-28	8364	No opposition during term of opposition
2008-07-17	8339	Ceased/non-payment of the annual fee